Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2023 07:00 ET | Source: Ikena Oncology, Inc.

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Favorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in minimal treatment-related proteinuria without any dose reductions or treatment...
November 07, 2023 08:00 ET | Source: Ikena Oncology, Inc.

Ikena Oncology to Present at Multiple November 2023 Investor Conferences

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today...
September 05, 2023 08:00 ET | Source: Ikena Oncology, Inc.

Ikena Oncology to Participate in September 2023 Investor Conferences

BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today...
August 10, 2023 08:00 ET | Source: Ikena Oncology, Inc.

Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update

Initial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter 2023 IK-595, best-in-class MEK-RAF complex inhibitor, investigational new drug (IND) submission planned by...
August 07, 2023 07:00 ET | Source: Ikena Oncology, Inc.

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena’s targeted oncology pipeline BOSTON and SOUTH SAN FRANCISCO,...
May 24, 2023 08:00 ET | Source: Ikena Oncology, Inc.

Ikena Oncology to Participate in Upcoming Investor Conferences

BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...
May 15, 2023 07:50 ET | Source: Ikena Oncology, Inc.

Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline

Lead targeted oncology program in Hippo pathway, IK-930, continues to advance through dose escalation with no dose-limiting toxicities observed to-date Preclinical data at AACR Annual Meeting...
May 15, 2023 07:45 ET | Source: Ikena Oncology, Inc.

Ikena Oncology Announces $40 Million Underwritten Offering

BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, announced...
April 20, 2023 08:00 ET | Source: Ikena Oncology, Inc.

Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days

BOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...
April 17, 2023 09:00 ET | Source: Ikena Oncology, Inc.

Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting

IK-930 is a potent Hippo pathway inhibitor that selectively binds TEAD1 and broadly represses oncogenic TEAD signaling IK-930’s differentiated paralog selectivity and robust repressor activity in...